Organization (Industry)
MEDLINE INC.
ClinicalTrials.gov lists MEDLINE INC. as lead sponsor of 41 trials, counting the companies grouped under it. MEDLINE INC. itself has 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Svazquca, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers MEDLINE INC. and 3 companies grouped under it: 41 lead-sponsored trials (0 its own, 41 in the grouped companies) and 3 legal-entity registrations (3 its own, 0 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Medline Industries | 39 | 0 |
| PluroGen Therapeutics, Inc | 2 | 0 |
| Centurion Medical Products | 0 | 0 |
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Burns | 4 |
| Pressure Ulcer | 3 |
| Varicose Ulcer | 2 |
| Varicose Veins | 2 |
| Cross Infection | 1 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 7 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 8 |
| 2017 | 1 |
| 2016 | 3 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: none of the 39 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Cyanoacrylate | 1 |
| Alcohol hand sanitizer foam | 1 |
| Post-market foam alcohol-based hand sanitizer #2 | 1 |
| Post-market foam alcohol-based hand sanitizer #1 | 1 |
| Chlorhexidine Gluconate | 4 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 17% hit target (n=18) | 50% on time (n=16) |
Journals published in (33)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of wound care | 4 |
| Annals of the New York Academy of Sciences | 3 |
| Chest | 3 |
| International wound journal | 3 |
| The journal of spinal cord medicine | 3 |
Showing 5 of 33 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 901 | 254 | 2025-12-16 |
FDA warning letters (2)
Shown in this order: most recent issue date first.
| Issue date | Letter |
|---|---|
| 2026-03-25 | medline-industries-lp-723866-03252026 |
| 2024-03-18 | medline-industries-lp-677545-03182024 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 75 |
FDA recalls (666)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Medline Micro-Kill Bleach Germicidal Bleach Wipes,7" x 8", 150 count, 150 count, Product Number MSC351400AN | Class II | 2026-06-30 |
| Medline Micro-Kill Bleach Germicidal Bleach Wipes, 6" x 5", 150 count, Product Number MSC351410AN | Class II | 2026-06-30 |
| Medline Micro-Kill Bleach Germicidal Bleach Wipes, 12" x 12", 110 Count, Product Number MSC351450AN | Class II | 2026-06-30 |
| Medline Micro-Kill Bleach Germicidal Bleach Wipes, 12" x 12", 110 Count Bag, Product Number MSC351450BG4 | Class II | 2026-06-30 |
| Medline medical convenience kits labeled as: 1) KIT PEDIATRIC OPEN HEART MOSES, Medline Kit SKU DYNJ910103B; 2) BASIC HEART CDS, Medline Kit SKU DYNJ910961A. | Class II | 2026-06-11 |
Showing 5 of 666 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 8 | 2025-02-13 |
Manufacturing and distribution sites (4)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Medline Industries, LP (f/k/a Medline Industries, Inc.) | Waukegan, US | FDA, Health Canada | |
| Medline Industries, LP | North Mankato, US | FDA | |
| MEDLINE INDUSTRIES, LP (Northpoint Services) | Waukegan, US | FDA, Health Canada | |
| Medline Industries, LP | Norristown, US | FDA |
Latest dated events (1,701)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-13 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-30 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-06-30 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-06-30 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 1,701 events.
Biomarker capability evidence (3)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial exclusion criteria |
| ALB | Trial sponsor | Mentioned in trial text |
| KIDINS220 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: active development programs, sec-reported annual financials, financing and grant events, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.